Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
July 15, 2021 09:00 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine...
Signati Medical Announces Second Animal Study Showing a New Bipolar Radio-Frequency Sealing Tool for Trans-scrotal Vasectomy.
May 24, 2021 12:00 ET
|
Signati Medical Inc.
Providence, RI, May 24, 2021 (GLOBE NEWSWIRE) -- Signati Medical, Inc., a medical device company focused on advancing men's health with a proprietary bipolar radio frequency sealing platform,...
Everwell Announces the Launch of Health and Wellness Clinic That Merges Conventional and Alternative Therapies
March 30, 2021 13:30 ET
|
Everwell Medical Management, Inc.
NEWPORT BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Everwell announces the launch of the Everwell health and wellness clinic, open now in Newport Beach, California. Everwell provides a select...
Signati Medical Announces Clinical Advisors
March 17, 2021 11:47 ET
|
Signati Medical Inc.
Providence, RI, March 17, 2021 (GLOBE NEWSWIRE) -- Signati Medical Inc. is pleased to announce the following doctors have joined their Clinical Advisory Board: Dr. Gerard Henry, MD; Dr. Tariq S....
Marius Pharmaceuticals Receives PDUFA Date for KYZATREX® NDA for Treatment of Hypogonadism
March 11, 2021 10:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal...
Life Extension's clinically-studied nutritional supplement supports healthy urinary function
February 02, 2021 10:00 ET
|
Life Extension
Fort Lauderdale, FL, Feb. 02, 2021 (GLOBE NEWSWIRE) -- No guy likes waking up in the middle of the night to “go.” But for many men, it isn’t an option: nocturnal urination leads to sleepless nights...
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX
January 28, 2021 10:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone...
Conversion Labs Annualized Revenue Run-Rate Hits $53.9 Million, up 332% vs. 2019, Driven by Subscriptions to an Expanding Suite of Telehealth Brands
December 15, 2020 08:31 ET
|
Conversion Labs, Inc.
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, reported its annualized revenue run-rate reached a record...
Conversion Labs July 2020 Revenues up 302% to Record $3.6 Million, Remains on Track to Exceed $40 Million in Revenue in 2020
August 03, 2020 08:31 ET
|
Conversion Labs, Inc.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported record revenues of $3.6 million in the month of...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
February 10, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...